Dendritic cell maturation in the tumor microenvironment

Open Access

Review

Table 1

Human LAMP3⁺ DCs described in the single cell transcriptomics of health and diseases

Diseases	Name	Markers	Description	Ref.
Pan-cancer	LAMP3⁺ DC	LAMP3, CCR7, FSCN1	Diverse functions	[61]
Pan-cancer	DC3	FSCN1, LAMP3, and CCR7	Present	[62]
Melanoma	DC3	CCL19, LAMP3, IDO1, IDO2, LAD1, FSCN1, CCR7	Immunostimulatory	[63]
Squamous cell carcinoma	migrating DC	PD-L1, PD-L2, IDO1, VISTA, LGALS9, TNFRSF14	Immunosuppressive	[64]
Rhabdoid tumors	LAMP3⁺ DC	FSCN1, LAMP3, CCL19, CCR7, CCL22, MARCKSL1	Present	[65]
Pancreatic cancer	Activated DC	LAMP3, CCL22, IL7R, IDO1	Immunosuppressive	[66]
Ovarian cancer	CCR7 DC	LAMP3, CCR7, CCL19, MGLL, FSCN1, IDO1, BIRC3	Present	[67]
Non-small-cell lung cancer	mregDC	LAMP3, CCL22, CCL19, BIRC3, FSCN1 and CCR7	Diverse functions	[68]
	DC3	FSCN1, LAMP3, CCL19, CCR7, CCL22, MARCKSL1	Present	[59]
	mregDC	Cd274, Pdcd1lg2, Cd200, Cd40, Ccr7 and Il12b	Immunosuppressive	[58]
	mature DC	LAMP3, CCR7, FSCN1,CCL19, CCL17, MARCKSL1, BIRC3	Present	[69]
	mregDC	FSCN1, CCR7, HLA-DR, CD86, PD-L1 and CD40	Present	[70]
Nasopharyngeal carcinoma	LAMP3⁺ DC	LAMP3, CCR7, FSCN1, IDO1,	Immunosuppressive	[71]
	DC3	CCR7, LAMP3, FSCN1, and CCL19	Diverse functions	[72]
	LAMP3⁺ DC	LAMP3, MARCKSL1, IDO1, CD80, CD83, CD40, CCR7, FSCN1	Immunosuppressive	[73]
Hepatocellular carcinoma	LAMP3⁺ DC	LAMP3, CD80, CD83, CCR7, CCL19, CCL21, FSCN1, IDO1	Immunosuppressive	[57]
Hepatocellular carcinoma	DC3	CCL19, LAMP3, and CCR7	Present	[74]
Head and neck squamous cell carcinoma	mregDC	ID2, BIRC3, CCR7, CCL19, LAMP3, CSF2RA	Immunosuppressive	[75]
	IDO1⁺ DC	IDO1, CCL17, and CCR7	Diverse functions	[76]
	mature cDC	CCL19, CCR7, CD274, LAMP3, CD40	Immunostimulatory	[31]
Esophageal squamous cell carcinoma	LAMP3⁺ DC	FSCN1, LAMP3, CCL22,TBC1D4, IDO1	Diverse functions	[77]
Esophageal squamous cell carcinoma	DC_3	CD40, FSCN1, CCR7	Present	[78]
Colorectal cancer	LAMP3⁺ DC	LAMP3, CCR7, FSCN1, CCL19	Present	[79]
Colorectal cancer	activated cDC1	Ccl22, Ccr7, Fscn1, Ccl5, Cd40	Immunostimulatory	[80]
Breast cancers	DC:LAMP	BIRC3, LAMP3, CCR7, IL7R	Present	[81]
	migDC	CCR7, CCL17, CCL19	Present	[82]
	mature DC	CCR7, LAMP3, CCL19, IDO1, and PD-L1	Present	[83]
Bladder urothelial carcinoma	LAMP3⁺ DC	LAMP3, CCR7, FSCN1,CCL19, CCL17, CCL22, SCTA, BIRC3	Immunosuppressive	[84]
Advanced osteosarcoma	CCR7⁺ DC	CCR7, CD74, CCL19	Present	[85]
Endometriosis	mature DC	LAMP3	Present	[86]
Chronic inflammatory skin disease	migratory DC	FSCN1, LAMP3, and CCR7	Present	[87]
Health and obesity	cDC2A	CD1C, IRF4, IL7R, CCL17, CCL22, CCL19 and LAMP3	Immunosuppressive	[88]
Cross-tissue integration	mregDC	CCR7, CCL22, LAMP3, EBI3, RAB8B, CERS6	Present	[89]
Human psoriasis	mregDC	CD200, BIRC3, LAMP3	Present	[90]
Adult healthy skin	migratory DC	CD83, CCR7, LAMP3, CD40, CD274, IDO1, CD83, CD86	Present	[91]
Healthy thymus	activated DC	LAMP3, CCR7, CCL19, CCL17, CD80, CD40, CD74	Immunosuppressive	[92]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.